Rinne Acta Neuropathologica Resubmission Supple_proof corrections 7

SUPPLEMENTARY FILES

Supplementary Tables

Table 1S Association between SUVR and percentage area quantitative immunohistochemical 4G8 estimate from biopsy sample
Variable
(N=45) / Parameter
estimate (SE) / p-value / 95% Confidence interval / Model R2
Biopsy Site
Pearson’s correlation coefficient / 0∙414 / 0∙0047
Full model / 0∙0047 / 0∙17
Intercept / -2∙41 (1∙40) / 0∙0926 / (-5∙24, 0∙42)
SUVR PET measurement slope / 2∙79 (0∙94) / 0∙0047 / (0∙90, 4∙68)
Contralateral
Pearson’s correlation coefficient / 0∙418 / 0∙0043
Full model / 0∙0043 / 0∙17
Intercept / -2∙19 (1∙32) / 0∙1038 / (-4∙85, 0∙47)
SUVR PET measurement slope / 2∙68 (0∙89) / 0∙0043 / (0∙89, 4∙47)
Composite
Pearson’s correlation coefficient / 0∙442 / 0∙0024
Full model / 0∙0024 / 0∙20
Intercept / -2∙23 (1∙25) / 0∙0811 / (-4∙74, 0∙29)
SUVR PET measurement slope / 2∙50 (0∙77) / 0∙0024 / (0∙94, 4∙06)
SE=standard error; SUVR=standardized uptake value ratio.
Table 2S Association between blinded visual PET image evaluation and Bielschowsky silver stain qualitative pathology assessment
Blinded visual evaluation / Qualitative pathology assessment* / Sensitivity and specificity
Positive (Abnormal) / Negative (Normal) / Sensitivity % (95% CI) / Specificity % (95% CI)
Reader 1
Abnormal / 8 / 2 / 100% (63%, 100%) / 93% (77%, 99%)
Normal / 0 / 26
Reader 2
Abnormal / 8 / 1 / 100% (63%, 100%) / 96% (82%, 100%)
Normal / 0 / 27
Reader 3
Abnormal / 7 / 1 / 88% (47%, 100%) / 96% (82%, 100%)
Normal / 1 / 27
Majority Read
Abnormal / 8 / 1 / 100% (63%, 100%) / 96% (82%, 100%)
Normal / 0 / 27
CI=confidence interval; Sensitivity=True positives / (True positives + False negatives); Specificity=True negatives / (True negatives + False positives).
*Bielschowsky silver stain not available from one study.
Table 3S Association between blinded visual PET image evaluation and ThioflavinS qualitative pathology assessment
Blinded visual evaluation / Qualitative pathology assessment / Sensitivity and specificity
Positive (Abnormal) / Negative (Normal) / Sensitivity % (95% CI) / Specificity % (95% CI)
Reader 1
Abnormal / 10 / 0 / 67% (38%, 88%) / 100% (87%, 100%)
Normal / 5 / 27
Reader 2
Abnormal / 9 / 0 / 60% (32%, 84%) / 100% (87%, 100%)
Normal / 6 / 27
Reader 3
Abnormal / 7 / 0 / 47% (21%, 73%) / 100% (87%, 100%)
Normal / 8 / 27
Majority Read
Abnormal / 9 / 0 / 60% (32%, 84%) / 100% (87%, 100%)
Normal / 6 / 27
CI=confidence interval; Sensitivity=True positives / (True positives + False negatives); Specificity=True negatives / (True negatives + False positives).


Table 4S Summary of Adverse Events by System Organ Class and Preferred Term (Total N=52)

System Organ Class
Preferred Terma / No. (%) of subjectsb
n=11 / No. of events
n=14
Ear and labyrinth disorders
Motion sickness / 1 (2) / 1
Gastrointestinal disorders
Abdominal pain upper
Nausea / 1 (2)
1 (2) / 1
1
Investigations
Blood pressure increased
Blood glucose decreased / 5 (10)
1 (2) / 5
1
Nervous system disorders
Dizziness
Headache / 2 (4)
1 (2) / 2
1
Respiratory, thoracic, and mediastinal disorders
Throat irritation / 1 (2) / 1
Vascular disorders
Flushing / 1 (2) / 1
N=total number of subjects; n=number of subjects or events in the category.
a Medical Dictionary for Regulatory Activities (MedDRA) Version 13.1.
b Some subjects experienced more than one AE.


Supplementary Figures

Figure 1S Association between biopsy site [18F]flutemetamol SUVR and percentage area quantitative immunohistochemical 4G8 estimate of amyloid β from biopsy samples. N=45

Figure 2S Association between contralateral [18F]flutemetamol SUVR and percentage area quantitative immunohistochemical 4G8 estimate of amyloid β from biopsy samples. N=45

Figure 3S Association between composite [18F]flutemetamol SUVR and percentage area quantitative immunohistochemical 4G8 estimate of amyloid β from biopsy samples. N=45


Figure 4S Association between percentage area of amyloid obtained with 4G8 staining versus Thioflavin S staining

Figure 5S Association between CERAD categories obtained with Thioflavin S versus percentage area of amyloid obtained with 4G8 staining